Canaccord Genuity Group Reiterates “C$4.25” Price Target for Cronos Group (TSE:CRON)

Canaccord Genuity Group set a C$4.25 price target on Cronos Group (TSE:CRON) in a report issued on Tuesday,BayStreet.CA reports. The firm currently has a buy rating on the stock.

Cronos Group Trading Down 3.3%

TSE:CRON opened at C$3.50 on Tuesday. Cronos Group has a 1 year low of C$2.27 and a 1 year high of C$4.66. The stock has a market cap of C$1.34 billion, a P/E ratio of 31.82, a P/E/G ratio of 0.12 and a beta of 1.13. The company has a debt-to-equity ratio of 0.17, a quick ratio of 24.01 and a current ratio of 24.24. The stock has a 50-day simple moving average of C$3.70 and a 200-day simple moving average of C$3.50.

Cronos Group (TSE:CRON) last issued its earnings results on Thursday, November 6th. The company reported C$0.07 earnings per share for the quarter. The business had revenue of C$50.60 million for the quarter. Cronos Group had a negative return on equity of 4.40% and a negative net margin of 42.65%. As a group, analysts anticipate that Cronos Group will post -0.26 earnings per share for the current fiscal year.

About Cronos Group

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S.